We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
- Authors
Ocean, Allyson J; Polite, Blase; Christos, Paul; Horvath, Lisa; Hamilton, Anne; Matulich, Daniel; Chen, Helen X; Sparano, Joseph A; Kindler, Hedy L
- Abstract
The bevacizumab-cetuximab combination has shown promising activity in chemotherapy-refractory metastatic colorectal cancer (mCRC). We sought to determine the safety and efficacy of cetuximab added to bevacizumab plus standard mFOLFOX6 (modified 5-fluorouracil [5-FU]/leucovorin/oxaliplatin) as first-line therapy for mCRC.
- Publication
Clinical colorectal cancer, 2010, Vol 9, Issue 5, p290
- ISSN
1938-0674
- Publication type
Journal Article
- DOI
10.3816/CCC.2010.n.042